Mice carrying human immunoglobulin transloci were immunised with HIV-1 gp140 antigen to gain insight into the range and nature of human monoclonal antibodies (mAbs) that can be elicited from such humanised mice. Using five-feature mice that harbour YAC-based germline-configuration human IgM, Igk and Igl transloci in a mouse background disrupted for endogenous mouse IgH and Igk expression, gp140-specific human IgM mAbs were readily elicited following serial immunisation. These mAbs were converted to human IgG1 format and were found to bind diverse epitopes within gp140, exhibiting high functional affinity for the antigen-typically in the nanomolar or sub-nanomolar range. The number of specific, stable hybridomas per mouse was, however, low (typically around five) with the hybridomas within individual mice often being clonally related. Nevertheless, different mice used B cell clones expressing varied V(D)J combinations, with affinity maturation through somatic hypermutation making a critical contribution. Thus, a wide range of distinct high-affinity mAbs can be obtained by immunising multiple animals. The results confirm the utility of the translocus-mouse approach and give insight into strategies for possible future improvement.
Introduction
Monoclonal antibodies (mAbs) account for a significant proportion of new drugs. A large proportion of the mAbs currently used in the clinic are either classical chimaeric mAbs (in which rodent variable (V) regions are linked to human constant (C) regions) or mAbs that have been generated through the grafting of the complementary-determining regions (CDRs) of antigen-specific mouse IgV regions onto human IgV region frameworks. In both cases, the therapeutic mAbs are produced using case-by-case humanisation from antigen-specific mouse mAb precursors (Reichert et al., 2005) . However, this humanisation approach is currently being superseded by technologies that allow the isolation of human mAbs directly from human immunoglobulin repertoires. There are several competing technologies in this area (Carter, 2006) . Where humans making suitable antibodies against the desired target can be identified, the rearranged immunoglobulin gene segments encoding these antibodies can be cloned out of the sorted or immortalised antigenspecific B cells. For other antigens, there is need for recourse to artificial systems of repertoire generation and/or antigenmediated selection. The main approaches followed have either used in vivo selection from humanised animals (typically mice) or have exploited display technology for in vitro selection. Although attempts have been made to obtain human mAbs from mice engrafted with human lymphoid tissue, the main successes with humanised animals have come from transgenic mice carrying human IgH and IgL loci in germline configuration: human mAbs can be isolated from such mice following appropriate immunisation. In the case of display (typically phage-based) technologies, in vitro selection is used to obtain high-affinity binders from synthetically diversified human antibody repertoires.
The choice of which approach to follow for human mAb isolation will depend on the nature and availability of the antigen, on access to the various technologies, on the range and nature of the binders required and on perceived likelihood of success. Here we focus on humanised mice, which underpin the generation of a high proportion of the mAbs that have most recently gained Food and Drug Administration approval (Nelson et al., 2010) . Some of these clinically useful human mAbs have been isolated from humanised mouse strains bearing large human immunoglobulin transloci, whereas others derive from strains carrying only a small number of human immunoglobulin V gene segments. Indeed, there is much to be learned about the general utility and workability of the technology such as the frequency of positive hybrids that can be anticipated from an individual immunised translocus mouse and the range of diversity of the mAbs that can be expected for a particular antigen. Such considerations will inform decisions about whether to follow the translocus mouse route or competing technologies, and help define the detailed strategy to pursue if the translocus mouse approach is followed.
Here, to gain information about the range and characteristics of the mAbs that can be obtained and the ease with which they are elicited, we have challenged a strain of mouse carrying human Ig transloci with a recombinant soluble antigen derived from the envelope glycoproteins (Env) of clinical isolates of HIV-1. We chose gp140 in part because it is an antigen that is in principle amenable to all the major technologies for human mAb isolation and therefore constitutes a good basis for comparison. However, we were also interested in ascertaining whether human (as opposed to mouse) antibody repertoires were especially suited for obtaining neutralising antibodies to HIV-1 in view of their larger D segments and resultant longer CDR3s, which have been suggested to be of benefit for such mAbs, possibly by reaching into the CD4-binding pocket Rizzuto et al., 1998; Pantophlet and Burton, 2006) . Several mouse strains have been described that carry human germline-configuration immunoglobulin gene loci extending from the early compact plasmid-based transgenes (Brüggemann et al., 1989; Taylor et al., 1992) through to a range of strains carrying larger transloci that have been generated by use of artificial chromosome engineering (reviewed in Lonberg, 2005 Lonberg, , 2008 . The one we used here (five-feature mice; Nicholson et al., 1999) carries the core section of the IgH locus (comprising all the D and J segments but only a restricted set of V H s linked to Cm) but reasonably extensive transgenic light chain loci (Fig. 1A) .
Materials and methods

Mice and immunisations
Five-feature mice (Nicholson et al., 1999) were maintained by in-breeding in our biomedical facility under UK Home Office Project Licence PPL80/2226. Immunisations were carried out by subcutaneous injection of recombinant soluble HIV-1 gp140 antigens (10 -30 mg in a volume of 100 ml; Jeffs et al., 2004 ) that had been emulsified in Freunds adjuvant (Sigma; complete adjuvant for priming with incomplete adjuvant for subsequent boosts) or mixed with either CpG-oligodeoxynucleotide Immuneasy (15 ml per vaccine dose; either from Qiagen, Crawley, UK or our own preparation) or the synthetic anionic polymer carbopol 974 (Particle Sciences Inv; to 0.5% (w/v) as previously described (Krashias et al., 2010) ) as adjuvant. Most mice were immunised with a 1:1 mixture of clade A (UG37; Imperial College, London, UK) and clade C (CN54; Polymun, Vienna, Austria) gp140 proteins except that mice FF1, 5, 6 and 8 were immunised and boosted with only CN54 gp140. Primary immunisation was typically at 12-16 weeks of age followed by four or five boosts at 4-week intervals. Antibody responses were monitored in serum samples obtained immediately prior to each booster immunisation. Two to three days after the final boost, hybridomas were established by fusing spleen cells with NS0 myeloma cells using PEG 1500 (Sigma-Hybri-Max), and distributing each fusion in the wells of 25 -50 96-well plates. Hybridoma supernatants were screened by enzyme-linked immunosorbent assay (ELISA) against mixed-clade gp140 antigens and positive clones were serially cloned by limiting dilution to establish stable hybridomas.
Cloning rearranged IgV genes and expression of recombinant IgG1s
The rearranged V H DJ H and V L J L genes expressed in the selected hybridomas were cloned by polymerase chain reaction (PCR) amplification of first-strand cDNA that had been generated by oligo-dT-primed reverse transcription of total hybridoma RNA. For the heavy chain, the primers for reverse transcription and PCR were a human Cm1 back primer together with a set of V H -family specific primers as described in Nicholson et al. (1999) . The Vl rearrangements were amplified using primers described in Tiller et al. (2008) and the Vk light chains amplified using a Ck back primer together with a consensus Vk primer as described in Nicholson et al. (1999) or with 5'-CTGGGGCTCCTGCT GCTCTGGTTCCCAG (Vk1D-12) or 5'-TTCATTTCTCT GTTGCTCTGGATCT CTG (Vk4-1). PCR products were either sequenced directly or following cloning to the vector TOPO blunt (Invitrogen, Paisley, UK).
For expression as recombinant human IgG1s, the rearranged V H and V L segments were PCR-amplified and cloned into the Igg1, Igk or Igl expression vector as described by Tiller et al. (2008) . For small-scale analytical studies, heavy and light chain expression vectors were transfected into 293T cells using GeneJuice (Novagen Merck), whereas for larger-scale preparations in three 175 cm 2 flasks, plasmid DNA (200 mg) was incubated at 328C for 4 h with 3 Â 10 7 293T cells in 50 ml Opti-MEM medium (Invitrogen) containing polyethylenimine (0.8 mM; branched chain, average mol. wt. 25 kDa (Sigma -Aldrich)). After 3 days of culture in 200 ml Dulbecco's modified Eagle's medium /0.05% fetal bovine serum at 328C, the recombinant IgG1 was purified from the culture supernatant by adsorption to protein A-Sepharose CL-4B (GE Healthcare) and dialysed into phosphate-buffered saline (PBS). The yield of recombinant IgG1 was typically 0.7 mg per flask.
Protein analyses
For ELISAs, plates were coated with recombinant gp140 (0.5 -1 mg/ml in PBS) or gp120 (1 mg/ml) and blocked with 1% skimmed milk powder. Hybridoma supernatants, purified recombinant IgGs or mouse sera diluted in PBS/1% bovine serum albumin were incubated on the plates for 90 min at room temperature: captured antibody was detected by incubation with horseradish peroxidase (HRP)-conjugated goat anti-human IgM (1:5000) or HRP-conjugated goat antihuman IgG (1:10 000) (both from Jackson Immunoresearch Europe, Soham, UK), developing with 50 ml TMB reagent (Pierce) and the absorbance measured at 450 nM. For binding inhibition assays, the binding of biotinylated mAbs to immobilised CN54 gp140 was competed by serial dilutions of the recombinant Hu-IgG mAbs. The biotinylated mAbs used were either 5F3 (specific for gp41 (Buchacher et al., 1994) or HJ16, HR10 or HGP68 (which recognise the CD4-binding site, V3 loop and V1/V2 loops respectively; Corti et al., 2010) . Biotinylated mAbs (at a concentration yielding 50% of maximum binding to the antigen-coated plates) were mixed with test IgGs at the indicated concentrations prior to incubating 60 ml aliquots on gp140-coated plates for 1 h at room temperature. After washing, bound biotinylated mAb was detected with HRP-conjugated streptavidin (1:1000; GE Healthcare, UK).
To determine binding kinetics by surface plasmon resonance using a Biacore 2000, recombinant gp140 CN54 and gp140 UG37 antigens were directly immobilised by amine coupling onto CM5 sensor chips at surface densities of 300-400 RU. The recombinant IgG1 mAbs in PBS were passed over the chip in 2-fold increasing concentrations from 15 to 500 nM at a rate of 50 ml/min allowing 2 min for association, followed by 8 min dissociation. Chips were regenerated with 0.2 M glycine pH 2.0. The sensograms were evaluated by fitting to a 1:1 Langmuir model using BIAcore Bia Evaluation software and a reference flow cell lacking immobilised ligand was used in calculation of the specific antigen -antibody response.
Results
Isolation of gp140-specific Hu-IgM mAbs
Five-feature mice were immunised with purified recombinant HIV-1 gp140 glycoprotein, employing one of three different adjuvants (Freund's complete and incomplete, commercial CpG formulation or carbopol) ( Table I ). Serum ELISA revealed that antigen-specific serum IgM was only readily detectable after the third boost with titres with all three adjuvants being relatively low, titrating out to 1:100 to 1:1000 even after multiple boosts (Fig. 1B) . This is similar to the titres previously obtained with this or similar humanised mouse strains following immunisation with a hapten-carrier conjugate (Nicholson et al., 1999; Magadán et al., 2002) .
In order to establish hybridomas, spleens were removed from mice 3 days after the last of multiple (in most cases, six) immunisations and fused with NS0 plasmacytoma cells. After fusion, cells were plated out in selective medium in 20-50 96-well plates with the intention (based on pilot experiments) that a well would contain either one or no (but rarely multiple) hybridomas. There was substantial variation between fusions with respect to the total yield of hybridomas obtained (mainly ranging from 500 to 4000) with, on average, 0.9% of the hybridoma supernatants scoring positive for gp140-specific IgM in an ELISA screen (Table I) . Following subcloning, a total of 79 stable gp140-specific hybridomas were obtained from the 17 fusions, of which 18 were selected for further molecular characterisation. Although hybridoma subcloning was necessary to achieve cell populations that stably expressed the human IgM gp140-specific mAbs, the frequency of such subclones was not substantially different to that which we have previously obtained in establishing hybridomas from conventional mice, suggesting that the human Ig transloci have not integrated into mouse chromosomes that are more readily lost following cell fusion than is the case with the chromosomes bearing the endogenous mouse Ig loci.
Structural diversity of Hu-IgM mAbs
The productive V H and V L rearrangements in the hybridomas were cloned into plasmid vectors following PCR amplification using V gene family-specific primers. With regard to V H usage, nearly all the hybridomas use V H 1.2 (Table II) . Although the V H 4.4 and V H 6.1 on the translocus can contribute to functional antibodies in this mouse, overwhelming use of the V H 1.2 segment appears to be an intrinsic feature of this transgenic IgH locus and has been observed in previous studies, independent of specific antigen challenge (Wagner et al., 1996; Nicholson et al., 1999) . However, the mAbs use a range of different V L s (though with a preference for V L s over V K s) and show diversity in their CDR3s (Table II and Fig. 2) . It is striking that all the gp140-specific mAbs carry somatic mutations within either (or both) their V H and V L segments with the sequence analysis revealing several cases of clonally related hybridomas (differing in the nature and extent of IgV somatic mutation) being obtained from an individual animal (Table II; Fig. 3 ).
Affinities and specificities of Hu-IgG derivatives
Of the 18 Hu-IgM mAbs selected for further characterisation, ELISA analysis revealed that 7 recognised both clade A and clade C gp140 antigens, whereas the remaining 11 were clade C-specific. We wished to confirm that immunisation of the five-feature mice did indeed provide a viable route to obtaining immunoglobulin variable regions that would endow an IgG antibody with high affinity for gp140 antigen, despite the fact that five-feature mice only make IgM antibodies. We therefore cloned the rearranged V H /V L segments from 12 of the selected mAbs into IgG expression vectors to produce recombinant Hu-IgG by transfection of 293T cells. Human IgG1 could be produced and purified in good yield by this approach (Fig. 4A) . The functional binding affinity of the recombinant IgGs for clade A and C gp140 proteins was All hybridomas derived from mice immunised with both clades A and C gp140, except that mouse FF6 was immunised with only clade C gp140.
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determined by surface plasmon resonance. The results (Fig. 5 , Table III) reveal that immunisation of the five-feature mice yielded Hu-IgM antibodies which, on conversion to IgGs, exhibit nanomolar-range affinities achieved through a varied balance of on-and off-rates. To gain insight into the range of epitopes recognised, we selected six of the Hu-IgG1 gp140-specific mAbs (6A, 8A, 8B, 13A2, 13B2 and 13C) for further investigation. We first asked whether they could bind recombinant gp120 component of the HIV-1 envelope antigen. Two of them (8B and 13B2) could not, suggesting that they might instead recognise gp41. Indeed, binding inhibition assays revealed that the 8B and 13B2 Hu-IgG mAbs are able to compete the binding of biotinylated 5F3 (a known gp41-specific mAb) to recombinant clade C gp140 (Fig. 4B) . The other four Hu-IgG mAbs tested (6A, 8A, 13A2 and 13C) bind both clade A and clade C gp140s, recognising the gp120 component. However, they recognise at least three different epitopes in gp120 with two of the four antibodies (6A and 13C) competing the binding of a mAb that recognises the V3 loop. The other two Hu-IgG mAbs (8A and 13A2) apparently interact with epitopes close to the CD4-binding site and V1/V2 loops, respectively ( Fig. 4C and D ; Table III ). Thus, the mAbs elicited from the five-feature mice recognise diverse epitopes within HIV-1 gp140.
Discussion
The experiments described here show that the five-feature mice can be used to obtain a range of antigen-specific human IgM mAbs that recognise diverse epitopes within the antigen (in this case HIV-1 gp140) and which, when converted to IgGs, bind with nanomolar, or sub-nanomolar, functional affinity. The work also gives some insight into strategies employed by the immune system to provide highaffinity binding sites, into approaches that could be followed to optimise the eliciting of mAbs from the five-feature mice and into issues that could be beneficially addressed in the creation of improved humanised mouse strains.
Although gp140-specific mAbs of high functional affinity were obtained from the five-feature mice, the yield was low-typically around 1% of the hybridomas obtained from mice that had been multiply immunised were found to be antigen-specific resulting in an average of about five stable gp140-specific mAbs from each hyperimmunised animal. Whereas a few dozen high-affinity mAbs specific for different epitopes on the antigen might suffice in many studies, a larger repertoire of mAbs may well be needed if searching for clinically useful HIV-specific antibodies. Previous investigations of the gp140-specific response in humans and mice have revealed that only a small proportion of the elicited mAbs exhibit broadly neutralising activity. Indeed, of the dozen mAbs subjected to detailed characterisation in this work only one (6A) has so far exhibited clear neutralising activity, although other neutralisers could be present among the initial pool of 79 stable hybridomas (unpublished work).
There is, however, substantial diversity in respect of the mAbs elicited from the five-feature mice. They recognise diverse epitopes on gp140 with binding inhibition assays, indicating that different mAbs bind epitopes in the vicinity of the CD4-binding site, around the V3 as well as V1/V2 loops as well as within gp41. Furthermore, from the structural perspective, although most hybridomas used a V H 1.2-comprising heavy chain (with this biased V H usage being an intrinsic characteristic of this mouse strain), there was nevertheless substantial diversity among the antibodies isolated with respect to the heavy chain CDR3 as well as to the nature of the light chain. Within an individual mouse, the multiple gp140-specific mAbs isolated did in many cases use different V(D)J rearrangements. However, in several instances, a single immunised mouse gave rise to two or three clonally related antigen-specific hybridomas.
The overall picture that emerges is that the antigen-specific hybridomas from within a single hyperimmunised mouse typically derive from one or small number of ancestral B cells which then undergo hypermutation and affinity maturation. However, the relevant ancestral B cells in different immunised mice carry different VDJ rearrangements. Thus, many different VDJ rearrangements appear able to yield an antibody from which a high-affinity gp140-specific mAb can be elicited through somatic hypermutation-but only a small number of such expanded clones can readily be obtained as hybridomas from an individual animal. Instead of using conventional hybridoma technology, it might be possible to rescue a larger number of mAbs from hyperimmunised fivefeature mice by PCR amplification of the rearranged V genes from antigen-sorted B cells, although a low frequency of antigen-specific B cells in the hyperimmunised five-feature mice might make this challenging. However, given that different individual five-feature mice contribute antibodies derived by maturation of distinct VDJ rearrangements, an alternative would simply be to establish hybridomas from a larger number of hyperimmunised animals.
It is interesting to consider what hints the results obtained in this work give with respect to assisting the future design of improved human translocus mouse strains. An obvious improvement would be to increase the number of V gene segments-especially on the IgH locus which provides little germline V H diversity in the five-feature mice. This would presumably increase the structural diversity of the mAbs elicited, although it might not necessarily have a dramatic Anti-HIV gp140 mAbs from human Ig-translocus mice effect on the overall frequency with which mAbs are obtained. The Xenomouse TM , which carries a substantially larger and more diverse IgH translocus, yielded a roughly 3-fold higher frequency of mAbs to EGF receptor than the frequency of gp140-specific mAbs obtained in this work (Davis et al., 1999) .
We are not, however, persuaded that it is especially important to try to create a mouse that harbours something approaching the full germline V gene repertoire of humans. Optimising the efficacy of affinity maturation could prove a more effective strategy for human mAb generation. Thus, all the anti-gp140 mAbs obtained in this work carry somatic mutations at either or both V H and V L and their generation obviously owes much to affinity maturation (as judged by comparison of clonally related sequences). This correlates nicely with previous work from both in vivo and in vitro systems showing that antigen-specific antibodies can be obtained by iterative mutation and selection even when starting with a drastically restricted primary repertoire (for example, see Xu and Davis, 2000; Cumbers et al., 2002) . One way to improve affinity maturation could be through the provision of cis-acting recruiting sequences. Thus, in the hybrids obtained in this work, the mutation load at V L is typically significantly greater than that observed at V H which, in keeping with previous observations (Wagner et al., 1996; Nicholson et al., 1999) , probably reflects a lack of Anti-HIV gp140 mAbs from human Ig-translocus mice some of the cis-acting sequences necessary for optimal recruitment of the somatic mutation machinery in the transgenic IgH locus. Indeed, it is clear that sequences downstream of Ca in the mouse IgH locus play an important role in controlling class -switch recombination (Vincent-Fabert et al., 2010) ; such sequences might well be implicated in optimising somatic mutation. An alternative strategy might be to increase the DNA deaminase activity of the AID enzyme, which triggers antibody diversification. Experiments in vitro have revealed that AID upmutants give increased antibody diversification (Wang et al., 2009) . It could well be that the specific activity of AID has been limited during evolution by the oncogenic effects of its off-target activity. It remains possible therefore that increasing the specific activity of AID could nevertheless improved antibody maturation in vivo.
The other aspect of the transloci that might bear improvement relates to the constant region of the IgH locus. The five-feature mice carry only Cm, lacking the other human downstream constant regions. Although it is widely thought that tethering of antigen to the surface of follicular dendritic cells (either through Fc receptors as part of antigen/IgG complexes or through CD21 as part of antigen/complement complexes) plays a major role in the selection process (see Haberman and Shlomchik, 2003) , our success in eliciting high-affinity anti-gp140 mAbs from the five-feature mice indicates that the selection can operate in the absence of FcR-bound IgG/antigen complexes. This is in keeping with the observations of Hannum et al. (2000) that antibody mutations characteristic of maturation to the hapten NP can accumulate in NP-immunised genetically engineered mice that do not make much antigen-specific serum immunoglobulin. However, while these findings indicate that engineering IgH transloci, which include an extensive complement of IgG constant regions, is unnecessary for eliciting highaffinity mAbs, we cannot exclude the possibility that including additional C-regions might nevertheless improve the maturation process.
Another issue relates to the identity of the C H genes on the IgH translocus. The hybridomas from the hyperimmunised translocus mice are essentially valued as a source of rearranged and mutated human V genes that confer desired antigen specificity. It therefore makes little difference to which C-region they are linked, as long as the mice allow production of the desired antigen-specific V genes. However, there is a possibility that the efficacy of B cell maturation and/or selection in the five-feature mice could be somewhat compromised by, for example, suboptimal interaction between the human IgM C-region within the B cell antigen receptor complex and mouse signalling components (e.g. CD79A/B). It would be interesting to know whether the performance of these mice could be improved by using mouse (rather than human) C-regions.
In light of recent developments in the immortalisation or cloning out of rearranged IgV gene segments from antigenspecific human memory B cells, an alternative way to generate human anti-gp140 mAbs is provided by directly accessing the memory B cells from HIV-infected individuals (Scheid et al., 2009; Corti et al., 2010) . This approach can yield large numbers of mAbs that may have the benefit of having been selected on naturally evolving antigen in vivo. However, in the case of antigens for which naturally immunised human donors are not available, phage display technology is likely to constitute the biggest competitor to the humanised mouse approach. Although very low-affinity binders can often be obtained with relative ease from naïve phage libraries, the isolation of high-affinity binding sites is usually a much more arduous undertaking and requires the antigen to be available in a readily handle-able format (Hoogenboom, 2005) . The results obtained here reveal that, even with a mouse strain harbouring a markedly incomplete version human immunoglobulin germline repertoire, a diverse array of high-affinity human mAbs can be readily obtained in a relatively facile way although the derivation of a large mAb repertoire may well require hyperimmunisation of many mice. Six of the mAbs were tested for epitope recognition by competition ELISA using reference antibodies of known binding specificity.
b
A dash indicates that no binding to gp140 UG37 was detected.
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